Masoud Azizad

2.5k total citations · 2 hit papers
8 papers, 364 citations indexed

About

Masoud Azizad is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Masoud Azizad has authored 8 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Infectious Diseases, 3 papers in Epidemiology and 2 papers in Surgery. Recurrent topics in Masoud Azizad's work include SARS-CoV-2 and COVID-19 Research (3 papers), Respiratory viral infections research (2 papers) and Lipid metabolism and disorders (2 papers). Masoud Azizad is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (3 papers), Respiratory viral infections research (2 papers) and Lipid metabolism and disorders (2 papers). Masoud Azizad collaborates with scholars based in United States, Australia and Canada. Masoud Azizad's co-authors include William A. Fischer, Joseph J. Eron, Katyna Borroto–Esoda, Robert W. Coombs, Wayne Holman, Myron S. Cohen, Elizabeth R. Duke, Katie R. Mollan, Amy James Loftis and Ralph S. Baric and has published in prestigious journals such as New England Journal of Medicine, Circulation and Science Translational Medicine.

In The Last Decade

Masoud Azizad

6 papers receiving 355 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

2021 230 citations William A. Fischer, Joseph J. Eron et al. Science Translational Medicine profile →
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia

2024 103 citations Christie M. Ballantyne, Szilárd Vasas et al. New England Journal of Medicine profile →

Peers

Masoud Azizad

ID

SURGE

EPIDE

CCM

MB

Jianxiong Liu China

Elías Cuesta‐Llavona Spain

Jingyu Su China

Shweta Birla India

Peirui Zhang China

Aixin Li China

Nguyễn Hoàng Bắc Vietnam

Anna Parfieniuk‐Kowerda Poland

Zhongfang Yan China

Jianxiong Liu China

Masoud Azizad

122 ×0.6

ID

34 ×0.5

SURGE

104 ×1.5

EPIDE

71 ×1.2

CCM

119 ×2.1

MB

Citations per year, relative to Masoud Azizad Masoud Azizad (= 1×) peers Jianxiong Liu

Countries citing papers authored by Masoud Azizad

Since Specialization

Citations

This map shows the geographic impact of Masoud Azizad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masoud Azizad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masoud Azizad more than expected).

Fields of papers citing papers by Masoud Azizad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masoud Azizad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masoud Azizad. The network helps show where Masoud Azizad may publish in the future.

Co-authorship network of co-authors of Masoud Azizad

This figure shows the co-authorship network connecting the top 25 collaborators of Masoud Azizad. A scholar is included among the top collaborators of Masoud Azizad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masoud Azizad. Masoud Azizad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Vasas, Szilárd, Masoud Azizad, Peter Clifton, et al.. (2024). †Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results. Journal of clinical lipidology. 18(4). e560–e560.

2.

Ballantyne, Christie M., Szilárd Vasas, Masoud Azizad, et al.. (2024). Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. New England Journal of Medicine. 391(10). 899–912. 103 indexed citations breakdown →

3.

Ballantyne, Christie M., Gerald F. Watts, Robert S. Rosenson, et al.. (2024). Abstract 4139852: Plozasiran and Triglyceride Levels in Hypertriglyceridemia: Long-Term Efficacy and Safety Data From Subjects in an Open-Label Extension Trial. Circulation. 150(Suppl_1).

4.

Vasas, Szilárd, Masoud Azizad, Peter Clifton, et al.. (2023). Abstract 17091: ARO-APOC3, an Investigational RNAi Therapeutic, Silences APOC3 and Reduces Atherosclerosis-Associated Lipoproteins in Patients With Mixed Dyslipidemia: MUIR Study Results. Circulation. 148(Suppl_1). 4 indexed citations

5.

Azizad, Masoud, Cameron R. Wolfe, Amy James Loftis, et al.. (2022). A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. UNC Libraries. 2 indexed citations

6.

Dougan, Marcelle, Ajay Nirula, Robert Gottlieb, et al.. (2021). Bamlanivimab+etesevimab for treatment of COVID-19 in high-risk ambulatory patients. 29(1). 33–33. 6 indexed citations

7.

Fischer, William A., Joseph J. Eron, Wayne Holman, et al.. (2021). A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Science Translational Medicine. 14(628). eabl7430–eabl7430. 230 indexed citations breakdown →

8.

Frishman, William H., et al.. (2002). Use of prostacyclin and its analogues in the treatment of cardiovascular disease.. PubMed. 1(1). 29–40. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact